Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid ...
Mesoblast (MESO) announced that it has entered into the Medicaid National Drug Rebate Agreement, NDRA, with the U.S. Centers for Medicare & ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...
Mesoblast (MSB:ASX; MESO:Nasdaq) has secured a significant agreement with the U.S. Centers for Medicare & Medicaid Services ...
Humans like to think that being multicellular (and bigger) is a definite advantage, even though 80% of life on Earth consists ...
23hon MSN
Every time the temperature drops, a cloud passes overhead, or the sun sets, a plant makes a choice: Keep its microscopic ...
Biological systems, once thought too chaotic for quantum effects, may be quietly leveraging quantum mechanics to process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback